Clinical Trials Browser

INDUSTRY × cobimetinib × Dermatologic × Clear all

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting

Melanoma

NCT07449754 2026-03-04

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Phase 2 Recruiting

Melanoma

NCT04109456 2026-01-15

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 3 FDA

Melanoma

NCT05260684 2025-03-06

OCEANMIST

716 enrolled 10 charts

Melanoma

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1 Terminated

CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03625141 2024-04-11

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Phase 2 Completed

80 enrolled 20 charts

Melanoma

NCT05756556 2024-02-01

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Phase 2 Suspended

Melanoma

NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2 Completed

113 enrolled 22 charts

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT01689519 2022-05-02

coBRIM

Phase 3 Completed

495 enrolled 15 charts

Melanoma

NCT03178851 2021-11-19

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

Phase 1 Completed

155 enrolled 22 charts

Melanoma

NCT01656642 2020-07-21

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT02768207 2019-08-28

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT01271803 2019-07-29

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Phase 1 Completed

131 enrolled 32 charts

Melanoma

NCT03139513 2019-01-22

MELANIS

Melanoma

NCT02457793 2018-11-20

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed

24 enrolled 27 charts

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms